Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 29,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 1 Clear all

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 520 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 19
States / cities: Harrisburg, Arkansas • Little Rock, Arkansas • Trumann, Arkansas + 15 more

Conditions: Brain Metastases
Interventions: Stereotactic Radiosurgery; Radiation
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pain
Interventions: Active CBD/THC Dose 1, Active CBD/THC Dose 2, matched placebo comparator; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 68 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Advanced Cancer
Interventions: RBS2418, Pembrolizumab, Other approved anti-cancer therapy; Drug
Lead sponsor: Riboscience, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more

Conditions: Alcohol Use, Unspecified
Interventions: Most hoped for future self, Most feared future self, Balanced future self, Control (trip to zoo); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 25 Years
Enrollment: 468 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy
Interventions: Risperidone; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: Metformin, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 60 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: PROSTATE CANCER
Interventions: Docetaxel and Prednisone, Radiation Therapy; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Crohn's Disease, Glycogen Metabolism, Inflammatory Bowel Disease (IBD)
Interventions: Empagliflozin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Crohns Disease
Interventions: TRX103, Cyclophosphamide; Biological · Drug
Lead sponsor: Tr1X, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more

Conditions: Epstein Barr Virus (EBV) Infection
Interventions: MVA-BN-EBV, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Delirium
Interventions: Ketamine (0.5 mg/kg), Normal Saline (placebo), Ketamine (1 mg/kg); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 746 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non Small Cell Lung Cancer
Interventions: Ipilimumab, Nivolumab, SBRT; Drug · Radiation
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Colorectal Cancer
Interventions: capecitabine, 5-fluorouracil, Surgical Resection, Radiation therapy; Drug · Procedure · Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Schizophrenia
Interventions: Aripiprazole, Risperidone; Drug
Lead sponsor: Kettering Health Network; Other
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Kettering, Ohio

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab, Truxima, Ruxience, Riabni; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 4
States / cities: Springdale, Arkansas • Clermont, Florida • Hattiesburg, Mississippi + 1 more

Conditions: Ulcerative Colitis
Interventions: sterile saline for injection, MDX-1100; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Port Orange, Florida • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: CBX129801; Drug
Lead sponsor: Cebix Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 22
States / cities: Escondido, California • Fresno, California • Irvine, California + 18 more

Conditions: Healthy
Interventions: vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Migraine
Interventions: Lu AG09222, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Interventions: Urelumab (BMS-663513); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 9 more

Conditions: Corneal Epithelial Degeneration
Interventions: TTHX1114(NM141) Ophthalmic Solution; Drug
Lead sponsor: Trefoil Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Graft Rejection, Kidney Failure
Interventions: cyclosporine or tacrolimus, sirolimus; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 8
States / cities: Tampa, Florida • Rochester, Minnesota • New York, New York + 4 more

Conditions: CNS Germ Cell Tumor
Interventions: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more

Search by objective public record fields.

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Narrative Writing to Promote Healthy Decisions About Alcohol During the Transition Out of College

Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions

Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

Treatment of Moderate to Severe Refractory Crohn's Disease

Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults

The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis

Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Dose Escalation TTHX1114 Ophthalmic Solution

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)